Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05957198 · ClinicalTrials.gov registry record
Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease
A clinical trial of Lung Diseases, Interstitial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 114,921
- Enrollment target
- 1
- Study location
NCT05957198 is a study of Lung Diseases, Interstitial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 114,921 participants, above the 1,016-participant average among 10 other Lung Diseases, Interstitial trials with a reported enrollment target (11211% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05957198, a study of Lung Diseases, Interstitial, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 114,921 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to describe initiation and use of oxygen therapy among patients with fibrotic Interstitial Lung Disease (ILD) and to assess the impact of oxygen therapy on clinical outcomes among patients with fibrotic ILD.
Conditions Studied
Study Locations (1)
Connecticut
- Boehringer Ingelheim Pharmaceuticals, Inc. - Ridgefield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114,921 participants |
| Start Date | 2023-07-25 |
| Est. Completion | 2023-09-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05957198
The ClinicalTrials.gov registry entry for NCT05957198 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 114,921 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,016-participant average among 10 other Lung Diseases, Interstitial trials with a reported enrollment target (11211% higher). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Diseases, Interstitial appearing as the primary indexed condition, and to 0 interventions.
NCT05957198 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT05957198 about?
NCT05957198 is a clinical study titled "Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease". The purpose of this study is to describe initiation and use of oxygen therapy among patients with fibrotic Interstitial Lung Disease (ILD) and to assess the impact of oxygen therapy on clinical outcomes among patients with fibrotic ILD.
What is the current status of trial NCT05957198?
This trial is currently completed. The enrollment target is 114,921 participants. The study started on 2023-07-25. Estimated completion is 2023-09-26.
What conditions does trial NCT05957198 study?
This clinical trial studies the following conditions: Lung Diseases, Interstitial.
Who is sponsoring clinical trial NCT05957198?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05957198 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Diseases, Interstitial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
RECRUITING · Phase 3
-
Dorothy P. and Richard P. Simmons Center for ILD Research Registry
RECRUITING
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
-
Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease
RECRUITING · Phase 1
-
Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation
RECRUITING · NA
-
Cough Capture as a Portal Into the Lung
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.